Humanigen, Inc
HGENDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001293310
Humanigen, Inc was delisted in 2023; its insiders filed their last Form 4 on Oct 20, 2023; 38 institutions reported holding it in 13F filings for Q2 2023, worth $842.2K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Humanigen, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Humanigen, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Black Horse Capital LP | 10% Owner | 8,398,871Indirect | Oct 20, 2023 | 0 |
| Chappell Dale | Chief Scientific Officer | 8,398,871Indirect | Oct 20, 2023 | 0 |
| Black Horse Capital Management LLC | 10% Owner | 8,398,871Indirect | Oct 20, 2023 | 0 |
| Cheval Holdings, Ltd. | 10% Owner | 8,398,871Indirect | Oct 20, 2023 | 0 |
| Black Horse Capital Master Fund Ltd. | 10% Owner | 8,398,871Indirect | Oct 20, 2023 | 0 |
| Morris Timothy E | COO and CFO | – | Jul 29, 2022 | 0 |
| Barliant Ronald | Director | – | Jul 29, 2022 | 0 |
| Durrant Cameron | Chief Executive Officer | 70,000Indirect | Jul 29, 2022 | 0 |
| Jordan Edward P. | Chief Commercial Officer | 12,500 | Jul 29, 2022 | 0 |
| Hohneker John | Director | – | Jul 29, 2022 | 0 |
| Boehm Rainer J. | Director | – | Jul 29, 2022 | 0 |
| Xie Yili Kevin | Director | – | Jul 29, 2022 | 0 |
| Buxton Cheryl | Director | – | Jul 29, 2022 | 0 |
| Kilcoyne Adrian | Chief Medical Officer | 12,000 | Jul 29, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2023 (view filing)6:50 PM ET | Oct 18 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −386.4K | $0.011 | −$4.25K | −4.4%8.40M after | 3 lots |
| May 20, 2022 (view filing)5:57 PM ET | May 18-20 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +1.04M | $2.17 | +$2.26M | +13.7%8.68M after | 9 lots |
| Mar 15, 2022 (view filing)6:23 PM ET | Mar 11 | 4 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +1.00M | $3.00 | +$3.00M | +14.4%7.94M after | 3 lots |
| Mar 14, 2022 (view filing) | Mar 8-9 | 6 daysLate | Kilcoyne AdrianChief Medical Officer | PPurchase | +12.0K | $2.63 | +$31.6K | New position12.0K after | 2 lots |
| Mar 10, 2022 (view filing)7:24 PM ET | Mar 8-10 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +468.5K | $0.01 | +$4.66K | –2.87K after | Derivative12 lots |
| Mar 4, 2022 (view filing)6:42 PM ET | Mar 2-4 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +996.8K | $0.0059 | +$5.87K | –5.69K after | Derivative15 lots |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Durrant CameronChief Executive Officer | PPurchase | +40.0K | $2.34 | +$93.6K | +133.3%70.0K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Jordan Edward P.Chief Commercial Officer | PPurchase | +12.5K | $2.32 | +$29.0K | New position12.5K after | |
| Aug 13, 2021 (view filing)9:28 PM ET | Aug 11-12 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −167.2K | $17.10 | −$2.86M | −2.2%7.27M after | 6 lots |
| Jul 30, 2021 (view filing)9:01 PM ET | Jul 28-29 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −39.1K | $17.04 | −$665.9K | −0.5%7.37M after | 6 lots |
| Jul 23, 2021 (view filing)8:32 PM ET | Jul 21-23 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −316.4K | $17.08 | −$5.40M | −4.1%7.39M after | 9 lots |
| Jul 16, 2021 (view filing)8:28 PM ET | Jul 14 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −15.2K | $17.06 | −$258.8K | −0.2%7.62M after | 3 lots |
| Jul 9, 2021 (view filing)9:01 PM ET | Jul 8-9 | 1 day | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −344.0K | $17.34 | −$5.97M | −4.3%7.63M after | 6 lots |
| Jul 2, 2021 (view filing)5:44 PM ET | Jun 30-Jul 2 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −463.1K | $17.19 | −$7.96M | −5.5%7.88M after | 9 lots |